Key result
Among over 8 million acutely ill hospitalized medical patients, VTE events occurred in 2%, and modeling indicated that universal pharmacological thromboprophylaxis would halve the number of events.
Why the study?
Does universal pharmacological thromboprophylaxis prevent VTE-related events in acutely ill hospitalised medical patients?
Observational (n=8,077,919)
Yes
Does universal pharmacological thromboprophylaxis prevent VTE-related events in acutely ill hospitalised medical patients?
Acutely ill medical patients have a high burden of VTE, and universal pharmacological thromboprophylaxis could potentially halve the number of VTE-related events during hospitalization.
Answers are grounded in this paper and cite their sources.
Modeling supports VTE reduction potential with universal thromboprophylaxis in medical inpatients; hypothesis-generating and leaves open need for RCTs.
The number of acutely ill hospitalised medical patients at risk for acute venous thromboembolism (VTE) has not been well defined. Therefore, we used the 2003 United States Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample database to estimate VTE events among hospitalised medical patients. We then modeled the potential reduction in VTE with universal utilisation of appropriate pharmacological thromboprophylaxis. We calculated that 8,077,919 acutely ill hospitalised medical patients were at risk for VTE. Heart failure, respiratory failure, pneumonia, and cancer were the most common medical diagnoses. We estimated that 196,134 VTE-related events occurred in 2003, afflicting two out of every 100 acutely ill hospitalised medical patients. These VTE-related events were comprised of 122,235 symptomatic deep venous thromboses, 32,654 symptomatic episodes of pulmonary embolism, and 41,245 deaths due to VTE. In our model, rates of pharmacological thromboprophylaxis prescription were low for various acute medical illnesses, ranging from 15.3% to 49.2%. However, with universal thromboprophylaxis, 114,174 VTE-related events would have been prevented. In conclusion, acutely ill medical patients represent a large population vulnerable to the development of VTE during hospitalisation. The number of VTE-related events would be halved with universal thromboprophylaxis. Further efforts focused on improving VTE prevention strategies in hospitalised medical patients are warranted.
No takes yet. Share an insight, caveat, or question.
Fanikos et al. (2009) conducted an observational in Acutely ill hospitalized medical patients at risk for VTE (n=8,077,919). Universal pharmacological thromboprophylaxis (modeled) vs. Current practice (low rates of prescription) was evaluated on VTE-related events (symptomatic deep venous thromboses, pulmonary embolism, and deaths due to VTE). Among over 8 million acutely ill hospitalized medical patients, VTE events occurred in 2%, and modeling indicated that universal pharmacological thromboprophylaxis would halve the number of events.
Synapse has enriched 10 related papers. Consider them for comparative context: